|
Public Health - VOSI Standard
STANDARD TO DELAY VACCINATING
NEWBORNS
1.0 SCOPE
1.1 This standard delays vaccinating newborns
until the Immunoglobulin E (IgE) in the umbilical cord blood
is tested in order to determine whether a newborn has a
compromised immune system that warrants delaying vaccination.
2.0 REFERENCED DOCUMENTS
2.1 Bakerman, Seymour, M.D., Ph.D. "A B
C’s of Interpretive Laboratory Data", Second Edition (
7th. Printing); Interpretive Laboratory Data, Inc.,
P.O. Box 7066, Greenville, N.C., 27835-7066; ISBN
0-945577-00=1; Copyright 1984
2.2 VOSI Research Report 13 – V50.3A
"Standard to Delay Vaccinating Newborns"
3.0 TERMINOLOGY
3.1 Hyper IgE - IgE in umbilical cord
blood is greater than 2.00 units/ml.
Note: Multiply conventional u/ml by 2.4 to
obtain international units in mg/liter. (Ref. 2.1)
4.0 SIGNIFICANCE & USE
4.1 Newborns are typically given the Hepatitis
B vaccine, since 1991, before leaving the hospital.
4.2 Ref. 2.1 specifies the following age
dependent maximum recommended IgE:
| Age |
Maximum IgE
U/ml
|
| Newborn |
2 |
| 1 - 11 months |
56 |
| 1 year |
83 |
| 2 years |
133 |
| 3 years |
101 |
| 4 years |
144 |
| 5 years |
148 |
| 6 years |
573 |
4.3 Less adverse reactions to vaccines will
occur when the immune system is strong enough to withstand the
stress of vaccination.
4.4 Ref. 2.1 states the following "causes
of elevation of serum IgE": parasitic infestations,
allergic disorder, immunological disorders of uncertain
pathogenesis, and neoplasm.
4.5. Based on the total of 1623 umbilical cord
samples, Ref. 2 verifies the accuracy of the 2 U/ml
established for maximum IgE.
4.6 The American Academy of Pediatrics (AAP),
FDA, CDC and all other groups that recommend vaccines should
reference this standard in their regulations and
recommendations in accordance with the National
Technology Transfer & Advancement Act of 1995 (NTTAA)
and the United
States National Standards Strategy which requires
enforcement by the National Institute of Standards &
Technology (NIST). VOSI
is one of the 210 "Private Sector Standards
Organizations" recognized by NIST (see www.voicesofsafety.com
...."About VOSI").
5.0 KEYWORDS
5.1 Hyper IgE, Immunoglobulin E, Immune System
This STANDARD was jointly
developed by VOSI/Childscreen (www.childscreen.org) under the
jurisdiction of Voices of Safety International (VOSI) committee
V50 on "Public Health", and subcommittee V50.3 on
"Screening Prior to Vaccination" (see www.voicesofsafety.com).
Copies are available FREE on-line at www.voicesofsafety.com
. . . Public Health, or from VOSI, 264 Park Ave.,
N. Caldwell, NJ 07006.
Ph (973) 228-2258, Fax (973) 228-0276
Updated:
2/14/2007
|